Orville Kolterman

Title(s)Associate Physician, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    DIABETES CONTROL AND COMPLICATIONS TRIAL
    NIH U01DK037828Jul 23, 1986 - Jun 30, 1994
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Medical Food Assessment Using a Smartphone App With Continuous Glucose Monitoring Sensors: Proof-of-Concept Study. JMIR Form Res. 2021 Mar 04; 5(3):e20175. Roux de Bézieux H, Bullard J, Kolterman O, Souza M, Perraudeau F. PMID: 33661120.
      View in: PubMed   Mentions:
    2. Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease. Gut Microbes. 2021 Jan-Dec; 13(1):1-28. Stoeva MK, Garcia-So J, Justice N, Myers J, Tyagi S, Nemchek M, McMurdie PJ, Kolterman O, Eid J. PMID: 33874858.
      View in: PubMed   Mentions:    Fields:    
    3. Leucine and Sildenafil Combination Therapy Reduces Body Weight and Metformin Enhances the Effect at Low Dose: A Randomized Controlled Trial. Am J Ther. 2021 Jan-Feb 01; 28(1):e1-e13. Rebello CJ, Zemel MB, Kolterman O, Fleming GA, Greenway FL. PMID: 33369909.
      View in: PubMed   Mentions:    Fields:    
    4. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020 07; 8(1). Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, Eid J, Gines J, Iyer M, Justice N, Loo WT, Nemchek M, Schicklberger M, Souza M, Stoneburner B, Tyagi S, Kolterman O. PMID: 32675291.
      View in: PubMed   Mentions:
    5. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2020 04; 72(4):613-626. Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC. PMID: 31697972.
      View in: PubMed   Mentions: 24     Fields:    
    6. Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664. Diabetes Care. 2019 08; 42(8):e137. Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM, DCCT/EDIC Research Group . PMID: 31332032.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care. 2019 04; 42(4):657-664. Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM, DCCT/EDIC Research Group . PMID: 30728218.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    8. Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. Obesity (Silver Spring). 2019 01; 27(1):59-67. Zemel MB, Kolterman O, Rinella M, Vuppalanchi R, Flores O, Barritt AS, Siddiqui M, Chalasani N. PMID: 30569637.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    9. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015; 8:241-53. MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O. PMID: 26056482.
      View in: PubMed   Mentions:
    10. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes. 2014 May; 63(5):1748-62. Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, Lorenzi G, Kolterman O, Sun W, Lachin JM, Natarajan R, DCCT/EDIC Research Group . PMID: 24458354.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    11. In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. Diabetes Technol Ther. 2013 Oct; 15(10):802-9. Micheletto F, Dalla Man C, Kolterman O, Chiquette E, Herrmann K, Schirra J, Kovatchev B, Cobelli C. PMID: 23865841.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    12. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013 May; 125(3):136-44. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, Maggs D, Kolterman OG. PMID: 23748514.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    13. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007 Nov; 30(11):2794-9. Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O. PMID: 17698615.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    14. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab. 2007 May; 3(5):E1; discussion E2. Edelman SV, Garg S, Kolterman OG. PMID: 17452962.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007 Feb; 30(2):210-6. Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, Rubin R, Fineberg N, Kolterman O. PMID: 17259483.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    16. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. PMID: 17003291.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    17. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2006; 2(1):69-77. Schnabel CA, Wintle M, Kolterman O. PMID: 17319471.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    18. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm. 2005 Apr 15; 62(8):816-22. Weyer C, Fineman MS, Strobel S, Shen L, Data J, Kolterman OG, Sylvestri MF. PMID: 15821274.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    19. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005 Jan 15; 62(2):173-81. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. PMID: 15700891.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    20. Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism. 2004 Sep; 53(9):1227-32. Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S, Kolterman O, Maggs D. PMID: 15334389.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    21. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004 Apr; 12(4):661-8. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C. PMID: 15090634.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    22. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004 Jan-Feb; 20(1):55-60. Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C. PMID: 14737746.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    23. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003 Nov; 26(11):3074-9. Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG. PMID: 14578242.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    24. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003 Jul; 88(7):3082-9. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. PMID: 12843147.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCTClinical Trials
    25. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 Mar; 26(3):784-90. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. PMID: 12610038.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    26. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003 Jan; 26(1):1-8. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR. PMID: 12502651.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    27. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002 Apr; 25(4):724-30. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. PMID: 11919132.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    28. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002; 4(1):51-61. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. PMID: 12017421.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    Orville's Networks
    Concepts (87)
    Derived automatically from this person's publications.
    _
    Co-Authors (3)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _